DDInter1042 DDInter1696
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004.
Solifenacin {u} (Compound) resembles {v} (Compound) Mequitazine
Solifenacin {u} (Compound) resembles {v} (Compound) Benazepril
Solifenacin {u} (Compound) binds {v} (Gene) CHRM4
Solifenacin {u} (Compound) palliates {v} (Disease) multiple sclerosis
Solifenacin {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Solifenacin {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Solifenacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Solifenacin {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Solifenacin (Compound) resembles Mequitazine (Compound)
Solifenacin (Compound) resembles Benazepril (Compound)
Solifenacin (Compound) binds CHRM4 (Gene)
Solifenacin (Compound) palliates multiple sclerosis (Disease)
Solifenacin (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Solifenacin (Compound) causes Atrial fibrillation (Side Effect)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Solifenacin may lead to a major life threatening interaction when taken with Potassium chloride